Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Novacyt launches IVDR-certified Yourgene Insight DPYD test in Europe

    Novacyt has introduced the IVDR-certified Yourgene Insight DPYD test for the European market and can now commercially distribute it in regulated markets. The test detects 19 clinically relevant variants in the DPYD gene, including all current tier‑1 and tier‑2 variants, and according to the company is the first CE-marked DPYD test under the IVDR with this variant coverage. Novacyt developed the product with clinicians and previously offered the test in May 2026 as research-use-only. » More on de.investing.com


  • Novacyt achieves 18% revenue growth in first half of 2026

    Novacyt reports H1 2026 revenue of £11.6m, an increase of 18% year on year. The instruments segment grew around 30% thanks to the LightBench Discover platform, while the clinical business rose by more than 20% driven by demand for non‑invasive prenatal tests and products for treating sickle cell disease. The acquisition of Southern Cross Diagnostics contributed £1.8m post‑acquisition; sales increased by over 30% in the Americas and by about 22% in Asia-Pacific. Novacyt is implementing a restructuring programme expected to deliver up to £4.0m in annual cost savings and anticipates IVDR approval for the DPYD kit in the coming months. » More on de.investing.com


  • Novacyt publishes annual report and financial statements for 2025

    Novacyt has published its annual report and financial statements for the year ended 31 December 2025 and made them available on the company website. The company, which specializes in molecular diagnostics, reports on its three business divisions—clinical diagnostics, instrumentation and research use only—and highlights its global presence in more than 65 countries. Novacyt lists locations in Le Vésinet, Manchester, Singapore, the USA and Canada, and notes the acquisition of Southern Cross Diagnostics in Australia in March 2026. » More on de.investing.com


  • Novacyt schedules general meeting for 30 June and announces investor presentation

    Novacyt will hold its annual general meeting on 30 June 2026 at 11:00 CEST at the Hilton Paris Charles de Gaulle. CEO Lyn Rees and CFO Steve Gibson will deliver an investor presentation on the day of the meeting via the Investor Meet Company platform; the presentation will have automatic French captions. Investors can register for the webinar through the platform; the following users will automatically receive an invitation. » More on de.investing.com


  • Novacyt: CSO Joanne Mason resigns with immediate effect

    Novacyt said Dr. Joanne Mason is stepping down from her role as chief scientific officer and board member with immediate effect to pursue new professional opportunities. Mason served in the role for six years and helped shape the scientific direction and R&D foundations of the molecular diagnostics company. The company gave no information on a successor or further details. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2022, Novacyt has already paid €0.00998 in dividends. The last payout was in July 2022.

Financials

In the last quarter, Novacyt had revenue of €13.27m and net profit of -€6.65m
(EUR) June 2026
YoY
Revenue 13.27m 132.65%
Gross profit 6.14m 22.44%
Net profit -6.65m 78.95%
EBITDA -4.46m 73.39%

Fundamentals

Metric Value
Market capitalization
€37.7m
Number of shares
72.47m
52-week high/low
€0.52 - €0.44
Dividends No
Beta
1.11
P/E ratio
-0.76
PEG ratio
-0.04
P/B ratio
1.42
P/S ratio
0.81

Company profile

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.

Name
Novacyt
CEO
Lyn Dafydd Rees
Headquarters Le Vésinet, if
France
Website
IPO
12/10/2012
Employees 234

Ticker symbols

Exchange Symbol
Euronext
ALNOV.PA
London Stock Exchange
NCYT.L
Pnk
NVYTF
Frankfurt
NYZ.F
DĂĽsseldorf
NYZ.DU
London
NCYT.L
Paris
ALNOV.PA
MĂĽnchen
NYZ.MU
🍪

Parqet  uses cookies. Learn more